Atlassian Free cash flow increased by 233.1% to $561.26M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.1%, from $638.32M to $561.26M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 16.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $189.61M | $58.12M | $193.87M | $308.24M | $190.23M | $75.95M | $146.49M | $349.68M | $270.19M | $163.29M | $284.26M | $554.87M | $412.63M | $74.34M | $342.57M | $638.32M | $360.32M | $114.60M | $168.52M | $561.26M |
| QoQ Change | — | -69.3% | +233.6% | +59.0% | -38.3% | -60.1% | +92.9% | +138.7% | -22.7% | -39.6% | +74.1% | +95.2% | -25.6% | -82.0% | +360.8% | +86.3% | -43.6% | -68.2% | +47.0% | +233.1% |
| YoY Change | — | — | — | — | +0.3% | +30.7% | -24.4% | +13.4% | +42.0% | +115.0% | +94.1% | +58.7% | +52.7% | -54.5% | +20.5% | +15.0% | -12.7% | +54.2% | -50.8% | -12.1% |